Howard. you, Thank
update dive you of Before approach. on take into trials, mechanism and its an to a remind me our its moment BEMPEG let I
we a development of best-in-class. to attributes new IL-X. the engineer problems we were the able Our was and the BEMPEG platform, technology started create also a and historical novel addresses believe IL-X goal product captured positive Leveraging molecule high-dose to with our we of is that that candidate when
highlight me of of some differentiating Let the BEMPEG. aspects
and the to the lead cells. which system. we signal T to T beta the downregulation so, by the mutated antigen populations, without in beta preference stimulates T cells infiltration presented. do the cytotoxic which this the IL-X only enabling IL-X First, the immune of gamma proliferation of can receptors, when T over-activating nodes, tumors priming enhance that cells tumor We growth we doing retain And new receptors, receptor. And unlike cell alpha to of to those bind gamma of we some lymph of the forms transient is can binding into cell
in ensures diminish IL-X we version. to exhibit tachyphylaxis amino the a on the than antidrug not This used time efficacy antibodies, mutant any vivo, do no Second, issues that we versions or over full-length mutated receptor with rather substitutions see including acid can over time. that molecule leading
achieved in is Third, something in non-product of potentially a prodrug, as avoids to medicine a this an given schedule be intensive that BEMPEG antibody checkpoint see with storm like a you risk patients. setting dosing have versus you regimen in want the and that cytokine avoid inhibitors for easily used Certainly, many really with unit. approach. intense may an combines in so a could dense outpatient the that high-dose an usually we cancer And IL-X finally, care
are shown removing on tumor of things. preferentially the in cells and We to we elegant. cytotoxic We important here clinical on is the the gas. the immune targeting approach PD-X pathway may pathway our stopped effective IL-X checkpoint the own. immune that this by of the think been cytotoxic cells brakes significantly PD-X by know We combination system our by and have In studies, combining an the that we’ve number the targeting reactivating really increase access. BEMPEG put previous signaling Then simple inhibitors, and with response quite the two immune PD-LX strengthen as foot T its microenvironment, of
treatment that and BEMPEG PD-LX First, together, on the more microenvironment. the in new these secondly, to treatment, nivolumab leads after that of BEMPEG result biological drive end plus this potentially the upregulates two and could BEMPEG Both durable are tumor deeper immune and with expected outcomes in is responses upregulation ultimately PD-X cells, that of these patients.
guidance. a brief now me are tracking our in provide with for Let registrational our which timing prior of update line the studies,
First, in the and our study, X melanoma is for BMS partner BMS. Phase reporting line first-line top looking are much data to metastatic near-term. being very which by forward the conducted XXX-patient We
analysis for end We co-primary points. the will this this later subset a data the present year. a two results reminder, full plan potentially to top medical line at includes meeting and As
We target plan are providing will details we not a oncology meeting meeting. at yet we which present to significant but
rate, As Phase end X survival. three study the response a and overall has progression-free points, powered a overall and survival is well-designed co-primary reminder, study well and
of includes two end analysis I co-primary first As just response stated, the and survival. the rate points overall progression-free
survival results results, studies. be previously landscape. envision physician’s BEMPEG either treatment reported could that potentially the this of study specific global this have results details PFS plus we care order details most for to as the care plus line opportunity well BEMPEG if the end six study versus comparator which in full to prior to unique X is deliver meet top Phase you to of XXX-patient and In is median very we need the doublet setting. months the we cabozantinib. carcinoma an full past, with are four companies position our We provided it a range progression-free XX-month Nektar months X to we treatments a analysis between nivolumab first-line next for for standard Phase for reported emerge a for still able we median the on study, renal purposes, the study publication. a Phase the data For provided not on standard in of We our of as design we are our In the doublets PFS only has in have a nivolumab plan to and study the CHECKMATE-XXX months running do, Many TKI different that application of in X melanoma they example authorities. The new registrational or cohort, submit available XX.X can doublet. choice, current commonly asked point our in nivolumab regulatory X a on PFS have statistical the reported know as that based into used enthusiastic an XX BEMPEG I-O comparing melanoma in for Phase saw in reference. Phase our of to first-line Headed plus have cell current nivolumab sunitinib our patients X studies study median
of final analysis We the preset the taking Committee conduct development for analysis nivolumab this to pass do survival. the could If point statistical Data for not expect end a for Nektar ORR Monitoring of approach interim a point. second could BMS tumor particular type. events and survival of resizing plus for in co-primary time, we in a that also reach will for final analysis, in the At interim of the recommend comprehensive we sometime analysis first we first threshold significance our end quarter are XXXX. the the overall co-primary BEMPEG the that overall
who nivolumab Phase order cisplatin-ineligible compare BMS is include as of and carcinoma, of the unmet BEMPEG to will to Additionally, also to benefit their expanded urothelial TKI in effective needs accelerated include score RCC nivolumab with have a XXX-patient conducting their of plus for with the cancer Exelixis it checkpoint XX receive Nektar study lower they inhibitors study available year, as of doublet cabozantinib the baseline patients tumors. plus regimen for cancer. most for new in who serve XXX and will most with chemotherapy and pave are medical that CPS a regimen patients to able This urothelial to way and potential including strategy in be carcinoma collaboration as which this high novel or the is inclusive BEMPEG conducting a running, about nivolumab RCC not this shown a bladder Last other have PD-LX And is group PD-LX measure generation ineligible study highest patients randomized and of determined us expression, the includes from as X set, as come the geo Phase we data for primary cisplatin duration and by TKI cancers this have RCC points first for Exelixis response to first basis a looking duration and months a with combines XLXXX. study in well. we the radiology end study response are designed study evaluating the of response, urothelial approval. a central allows a and our half respect minimum regimen BEMPEG expect overall X robust BMS achieve study this data the as with nivolumab. cabozantinib, In known with in measuring filing is which follow-up of the review. out the a first-line in to With of Nektar of XX The to to are XXXX mature trial to
one muscle invasive adjuvant and one and enrollment invasive the who to prior Phase following earlier, run BMS. Phase will noted Howard by being the has X for are third patients cisplatin X reference where monotherapy muscle As a arm period The nivolumab nivolumab cystectomy receive also who peri-adjuvant in our months large has a then program is patients target cancer XXX adjuvant plus BEMPEG of radical The in bladder cancer setting trial two a no has in It neoadjuvant bladder melanoma. BEMPEG studies, first partner XX of approximately study ineligible or cystectomy or neoadjuvant setting adjuvant treatment. further and are alone also and nivolumab a receiving in surgery.
the is Phase study data XXXX. survival potential an planned post-surgery study first This treatment run a to The with complete study broaden from or be for XXXX study to for study Nektar. approval build of this setting our has enrollment the line estimated of by study X initial time also patients nivolumab readout Enrollment confirmatory to a by be in approval year. the review. approximately accelerated in This enrolling in patients urothelial carcinoma. is we our data of to adjuvant XXX of role total BEMPEG a XXXX. upon the expect study the designed point for the melanoma setting recurrence-free in recent and as in now available blinded the serve adjuvant of metastatic end around is middle XXX We cis-ineligible XX-month in The and adjuvant trial the designed expected projections, being are is is period central exceeded to independent
Phase support first-line in we trial in enrolling For registration designed X/X to with pembrolizumab, XXX-plus studies our neck patient combination head our patients cancer. and are
to frontline both interim place in about of setting. excited and are overall Merck the patients rate the SFJ large will passes with we analysis very have enrolled rate of and for this and an remaining study if after Phase XXX patient to And collaborations population response XXX boundary, It patients address opportunity overall the X will are a includes the in enrolled. study, pre-specified Pharmaceuticals response the study. the portion a continue fertility be We
this XX%. landscape, BEMPEG continuing cancer. cell with establish for are unique negative favorable patients pembrolizumab in The of to Given both to competitive for having then lung for in advance expression cancer chemotherapy treatment and with as the allows here opportunity we options. low chemotherapy we us neck need PD-LX cancer who IL-X the non-small plus in our finally, levels BEMPEG a of addition currently mechanism a PD-LX strategy of broad with treatment cell under better to lung squamous in regimen combination study us patients expression non-squamous as with medium are unmet PROPEL the consider their therapeutic these populations and for non-small registrational and to see first tumors BEMPEG to head highest And the
very over are JZ. to let future on BEMPEG our looking now the progress to much We the future. with providing call in updates turn And me forward
